Healthcare Stocks Lower: Argenica, BCAL Diagnostics and Invex in Focus

Sonal Goyal

03 November 2026 04:30 PM AEDT

Healthcare Stocks Lower: Argenica, BCAL Diagnostics and Invex in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

BCAL Diagnostics (ASX:BDX) fell 14.63% to 7 cents during the 3 November 2026 session.
Argenica (ASX:AGN) traded at 11.5 cents, down 11.54%, and Invex (ASX:IXC) traded at 9 cents, down 10.00%.
The three companies have reported clinical, product or corporate updates in the past week, each dated on or before 30 October.
The S&P/ASX 200 eased about 0.12% to 8,846.20 in the same session.

Three healthcare names fall in the same session

Three ASX-listed healthcare companies finished lower in the 3 November 2026 session. BCAL Diagnostics Ltd (ASX:BDX) fell 14.63% to 7 cents, Argenica Therapeutics Ltd (ASX:AGN) slipped 11.54% to 11.5 cents and Invex Therapeutics Ltd (ASX:IXC) dropped 10.00% to 9 cents. The S&P/ASX 200 eased about 0.12%, or 10.30 points, to 8,846.20 over the same session. Their latest updates were released on 30 October 2026, and none is dated 3 November.

BCAL Diagnostics (ASX:BDX)

BCAL's September quarter report said it had completed clinical validation of BREASTESTplus 2 for women aged 30 and over, with sensitivity of 80.3% and specificity of 48.5% for early-stage breast cancer. A November 2026 launch is targeted in Sydney, Melbourne and Brisbane, subject to accreditation. The company also introduced Avantect Multicancer in select Sydney and Melbourne locations.

Argenica Therapeutics (ASX:AGN)

Argenica's quarterly update said it is designing a late-stage trial of xaranetide in moderate to severe acute ischaemic stroke, with drug Manufacturing progressing with Corden Pharma. Cash was $5.4 million at 30 September 2026, and the company holds up to $1.5 million in non-dilutive funding for the trial.

Invex Therapeutics (ASX:IXC)

Invex agreed to acquire Rekover Therapeutics, a New Zealand company developing nalfurafine for multiple sclerosis-related optic neuropathy. Consideration is 45 million shares plus performance rights, with no cash payable. The company is raising $10 million at 8 cents per share, to fund the REVIVE study, with a general meeting expected in early December.

Sector context

Early cancer detection, stroke therapeutics and neurology Drug Development are all areas where clinical results and regulatory steps determine progress. Smaller companies in the sector often rely on grants, partners and Equity raisings to fund trials.

Risks

Each company's program depends on clinical or regulatory outcomes that are not yet known. BCAL's launch is subject to accreditation, Argenica's trial needs further funding and Invex's Acquisition depends on Shareholder and expert approvals and on milestones.

What to watch next

Investors will be watching BCAL's November launch, the finalisation of Argenica's trial protocol and Invex's December general meeting.

The Final Word

The three healthcare stocks traded lower on 3 November 2026. Their most recent updates focused on a diagnostic launch, a late-stage trial design and an acquisition, with the next milestones still to be reached.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.